PanaThera, Inc. develops gene therapy products and services for patients suffering from devastating diseases which lack effective therapies. PanaThera’s current focus is the development of novel therapies for amyolateral sclerosis. Its therapeutic platforms include adeno-associated virus, lentivirus, and other emerging viral vectors.